Teon Therapeutics is developing a portfolio of single-target small molecules that affect metabolic signaling pathways in the tumor microenvironment. Our pipeline consists of first-in-class and best-in-class candidates with targets that affect both immune and cancer cells.
Cancer immunotherapies have demonstrated clinical efficacy in different types of cancer. However, many tumors show significant resistance to checkpoint blockade presumably due to insufficient rectification of the immunosuppressive tumor microenvironment (TME) and the limited reinvigoration of antitumor immunity.
Teon takes a unique approach to improve the TME and reinvigorate anticancer immunity:
Targeting key GPCRs and enzymes in the TME that are upregulated on immune cells and cancer cells
Developing a synergistic pipeline of first-in-class and best-in-class compounds across the TME metabolic signaling pathways
TME (Tumor Microenvironment)
Teon can antagonize metabolic pathways that suppress antitumor immunity and promote cancer cell proliferation
The immunosuppressive state of the TME is regulated by the metabolic activity of cancer cells. Rapidly proliferating cancer cells require high levels of energy and therefore metabolic reprogramming has emerged as a key feature for cancer survival under hypoxia, stress and limited nutrient availability. Metabolic reprogramming generates large amount of metabolites that not only alter the TME, adversely affect the survival and function of immune cells but also directly stimulate cancer cell proliferation. The common feature of this metabolic reprogramming is that cancer cells switch their glucose metabolism toward “aerobic glycolysis” (Warburg effect), thus decreasing glucose availability and increasing lactic acid in the TME. The hypoxic, glucose-deprived and lactic acid-enriched TME impairs T cell function and thus antitumor immune response. Metabolic stress leads to the release of the danger signal molecule ATP into the TME. ATP is rapidly converted to adenosine, which activates adenosine receptors (A2A and A2B) on immune cells and cancer cells and consequently inhibits immune function and promotes cancer cell survival. Aberrant lipogenesis is another key feature of metabolic reprogramming in cancer cells. While lipids provide additional energy required by proliferating tumor cells, their metabolites, such as prostaglandin E2 (PGE2), can dampen the function of immune cells through activation of EP4 receptors.
Lina Yao, MD, PhD
Jim Liu, PhD
Elfatih Elzein, PhD
Robert Sikorski, MD, PhD
Peter Fan, PhD
Sami Karaborni, PhD
Veronique Lauriault, PhD, DABT
Lou Lange, MD, PhD
Lina Yao, MD, PhD
Eric Small, MD
David Dornan, PhD
Brent Blackburn, PhD
Ivan Diamond, MD, PhD
Teon Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020
Teon Therapeutics, Inc. has been invited to present at the Fall Private Company Showcase hosted by Solebury Trout, BMO and Davis Polk which is being held virtually on October 15, 2020. Teon is scheduled to present on October 15 at 11:40am PT, with one-on-one meetings to be held throughout the conference.
Teon Therapeutics Appoints Biotech Veteran Louis Lange as Independent Board Member
Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointed of Louis Lange, MD, PhD, to its board of directors. Dr. Lange is a renowned academic Chief of Cardiology and biotech veteran, having founded CV Therapeutics in 1992 and served as its Chairman, CEO and CSO.
Teon Therapeutics Appoints Ken Horne as President & Chief Operating Officer
Teon Therapeutics, a pharmaceutical company developing novel small molecules focused on GPCR targets for oncology indications, today announced the appointment of Ken Horne as President and Chief Operating Officer. With this appointment, Mr. Horne will take responsibility for operations, business development and fund raising for Teon Therapeutics.